Insecticides India Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/7eoutaasjm5zr0bwphlg6837.pdf

Key Takeaways


The Inventory Overhang & Margin Reset

Rajesh Aggarwal: "I'm very, very confident by the end of this quarter, our inventory should be somewhere in the range of INR550 crores minus, not INR550 crores-plus."

The Q2 Bet: New Products & Seasonal Peak

Rajesh Aggarwal: "Q2 anyway is the highest. And lot of contribution is going to come from the new products. So yes, Q2, you can take it as it will be having the best performance, both in terms of top line and bottom line, yes. There can be surprises in Q2."

Strategic Pivot: From Generics to IP-Led Portfolio

Rajesh Aggarwal: "We have a very clear strategy that we will bring the new technology and new technology products to the market. Slowly, we'll be doing the tail cutting of the generics, and we'll give value-added products to the customers because we believe that ultimately, it is the solution which a customer wants. They don't need the product."

Capex & Capacity Build-Out


Exports & Registrations


Guidance & Commitments

CommitmentSpecificsTimeline
Q2 EBITDA marginDouble-digit margin targetedQ2 FY24
Full-year EBITDA margin9% to 10%FY24
Inventory reductionInventory at ₹550 crore minusBy end of Q2 FY24
Domestic revenue growthMinimum double-digit growth, top line and bottom lineFY24
Export revenue₹150 crore to ₹200 crore (vs ~₹200 crore target)FY24
New product launchesAt least 7-8 products in herbicide, insecticide, fungicideFY24-FY25
Dahej plant production startPost-DiwaliFY24
Sotanala project completion2-year projectStarting post-Diwali 2023
IIL Biologicals launchAfter Diwali, catching small rabi seasonFY24
Capex spend₹150 crore (₹100 cr Sotanala, ₹25 cr SEZ, ₹25 cr Dahej)Next 2 years
Revenue CAGR20%Next 5 years
Annual margin improvement100-150 bps year-on-year at EBITDA levelOngoing, post recovery year
FY24 revenue growth12%FY24

Key Metrics

MetricQ1 FY24
Revenue from operations₹639.95 cr, growth of ~14.14% YoY
EBITDA margin7.13%, impacted by liquidation of high-cost inventory from previous year
High-cost inventory liquidation~41% of overall sales during the quarter
Maharatna products sales₹257.74 cr, 61.49% of total branded formulation sales, up from ₹209.06 cr (56.37%) in Q1 FY23
Category-wise sales: Herbicide64% of total sales
Category-wise sales: Insecticide30% of total sales
Category-wise sales: Fungicides4% of total sales
Category-wise sales: Biological and PGRs~2% of total sales
Region-wise revenue: North~36% of total revenue
Region-wise revenue: West~35% of total revenue
Region-wise revenue: South~22% of total revenue
Region-wise revenue: East~7% of total revenue
Segment-wise revenue: B2C~66% of total revenue
Segment-wise revenue: B2B~31% of total revenue
Total inventory~₹600 cr as of the call date, down by ₹250 cr from peak
FY24 revenue growth guidance12% for the full year
FY24 EBITDA margin expectation9% to 10% for the full year
5-year revenue CAGR target20%
Export revenue target for FY24₹150 cr to ₹200 cr, with a possible downfall of 20%–25% in exports assessment
Focused Maharatna products contribution~35% of turnover, from about 1 dozen products
Maharatna products contribution~30% of turnover, from about 2 dozen products
Gold (generic) products contribution30% to 35% of turnover
Silver (tail cutting) products contribution2% to 3% of turnover
Average price cut in generic segment~10% plus
New product launches lined up in Q2 FY244 launches, 3 herbicides and 1 insecticide
Total capex planned over next 2 years₹150 cr, including ₹100 cr for Sotanala, ₹25 cr for SEZ expansion, ₹25 cr for Dahej
Dahej plant completion95% of expenses already done, production to start post Diwali
Chopanki technical plant capacity increase~50%
Biological revenue contribution1.5% to 2% of total turnover
Target annual EBITDA margin improvement100 to 150 bps year-on-year
Inventory reduction target by end of Q2 FY24Below ₹550 cr